Eli Lilly and Company
LLY · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -24.13 | 0.29 | -1.79 | 0.11 |
| FCF Yield | 1.26% | 0.18% | -0.22% | 0.10% |
| EV / EBITDA | 90.97 | 98.14 | 186.68 | 125.83 |
| Quality | ||||
| ROIC | 7.81% | 8.80% | 6.82% | 9.15% |
| Gross Margin | 82.91% | 84.27% | 82.53% | 82.24% |
| Cash Conversion Ratio | 1.58 | 0.55 | 0.60 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.82% | 21.74% | 20.96% | 16.43% |
| Free Cash Flow Growth | 571.24% | 180.14% | -320.33% | 258.34% |
| Safety | ||||
| Net Debt / EBITDA | 4.15 | 4.87 | 8.51 | 5.28 |
| Interest Coverage | 43.04 | 28.62 | 22.19 | 25.80 |
| Efficiency | ||||
| Inventory Turnover | 0.25 | 0.22 | 0.24 | 0.32 |
| Cash Conversion Cycle | 336.38 | 354.63 | 336.50 | 251.55 |